This article is more than 5 years old. Information may no longer be current.
Vitrase improves acuity after vitreous hemorrhage, subgroup analysis finds
Click Here to Manage Email Alerts
Intravitreous injection of hyaluronidase improved visual acuity earlier in more patients than did saline injection, according to a recent study.
The study of the use of Vitrase (ovine hyaluronidase, Ista) in patients with vitreous hemorrhage who did not have age-related macular degeneration was presented as a poster at the American Academy of Ophthalmology meeting last month in Chicago.
R.M. Lieberman, MD, and colleagues analyzed pooled subset data from two phase 3 clinical trials to assess the efficacy of Vitrase for improving best corrected visual acuity after vitreous hemorrhage. Patients in the trials were injected with 55 IU or 75 IU of Vitrase or with saline.
At 1 month after treatment, 25% of subjects treated with Vitrase had at least a three-line improvement in BCVA, while it took 57 days for 25% of the patients in the control group to achieved a three-line improvement, the study authors said.
By 3 months after a single injection of Vitrase, 48.2% of people in the 55 IU group and 46.8% of people in the 75 IU group had achieved at least a three-line improvement in BCVA, compared with 37.3% in the control group.